Significance of continuous surveillance of anti-endothelial cell antibody in patients with chronic obstructive pulmonary disease_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

XUE Huihong ¹ ,  ZHANG Cheng ^1,2 , ZHANG Xiangyan ^1,2 , SHAO Songjun ^1,2 , TIAN Yang ^1,2

1. Department of Respiratory and Critical Care Medicine, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550000, P. R. China;
2. Key Laboratory of Pulmonary Immune Diseases, National Health Commission, Guiyang, Guizhou 550000, P. R. China;

Corresponding author：

ZHANG Cheng, Email: zhangcheng16@sina.com

Keywords：

Chronic obstructive pulmonary disease; Anti-endothelial cell antibody; Disease progression

DOI：

10.7507/1671-6205.202104013

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the significance of continuous surveillance of anti-endothelial cell antibody (AECA) in patients with chronic obstructive pulmonary disease (COPD) in one year.Methods Thirty-six patients with acute exacerbation of COPD and 93 patients with stable COPD were selected from Guizhou Provincial People's Hospital from October 2019 to February 2020, thirty healthy people in the same period were selected as normal control group. In the stable phase group, >386.17 pg/mL was included in the higher group, and <386.17 pg/mL was included in the lower group according to the AECA median (386.17 pg/mL). According to the grouping criteria, the patient with the AECA median was omitted, the sample size of AECA higher group and lower group accounted for 46 cases, respectively. AECA test, lung function examination, the number of acute exacerbations in the past 1 year and MMRC score were performed for each group; At the same time, all the above contents were followed up dynamically.Results 1. Comparison of AECA levels among the three groups: the acute exacerbation COPD group was higher than the stable phase group and the normal control group, and the stable phase group was higher than the normal control group, with statistical significance (all P<0.05). 2. Overall comparison of related indicators before and after follow-up in COPD stable period group: AECA level was higher than baseline after follow-up, and the follow-up after 12 months was higher than that after 6 months; After 12 months, forced expiratory volume in one second (FEV₁), the ratio of FEV₁ to forced vital capacity (FVC), and FEV₁%pred were all lower than baseline, and the first two indexes were lower than those after 6 months follow-up. The number of acute exacerbations and mMRC score after 12 months were higher than that after 6 months follow-up, with statistical significance (all P<0.05). 3. Comparison of related indicators after follow-up between the higher and lower AECA groups: Follow-up after 12 months showed that AECA, the number of acute exacerbations and mMRC score in the higher AECA group were all higher than those in the lower AECA group at the same period, and the number of acute exacerbations and MMRC score in the higher AECA group were higher than those in the lower AECA group at 6-month follow-up. The FEV₁, FEV₁%pred and FEV₁/FVC of the higher AECA group followed up after 12 months were lower than those of the lower AECA group at the same period, and the FEV₁ and FEV₁%pred of the higher AECA group followed up after 6 months were lower than those of the lower AECA group at the same period, and all the differences were statistically significant (all P<0.05).Conclusion Abnormality of AECA expression in COPD may be associated with continued decline in lung function, number of acute exacerbations in the previous 1 year, and increased mMRC score, and therefore may be associated with continued progression.

Citation： XUE Huihong, ZHANG Cheng, ZHANG Xiangyan, SHAO Songjun, TIAN Yang. Significance of continuous surveillance of anti-endothelial cell antibody in patients with chronic obstructive pulmonary disease. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(8): 536-541. doi: 10.7507/1671-6205.202104013 Copy

1.	Vogelmeier CF, Criner GJ, Martínez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Arch Bronconeumol, 2017, 53(3): 128-149.
2.	Cheng G, Zhang N, Wang Y, et al. Antibodies of IgG, IgA and IgM against human bronchial epithelial cell in patients with chronic obstructive pulmonary disease. Clin Lab, 2016, 62(6): 1101-1108.
3.	Scambler T, Holbrook J, Savic S, et al. Autoinflammatory disease in the lung. Immunology, 2018, 154(4): 563-573.
4.	Wen L, Krauss ES, Petersen F, et al. Autoantibodies in chronic obstructive pulmonary disease. Front Immunol, 2018, 25(9): 66.
5.	韦薇, 沈雅萍, 杨翌翔, 等. 血清中抗内皮细胞抗体检测对狼疮性肾炎患者的价值. 国际检验医学杂志, 2017, 38(6): 822-824.
6.	Moroncini G, Svegliati BS, Gabrielli A. Agonistic antibodies in systemic sclerosis. Immunol Lett, 2018, 195: 83-87.
7.	马丽, 张璐, 张程, 等. 抗血管内皮细胞抗体在吸烟肺气肿大鼠肺泡隔细胞凋亡中的作用及甲泼尼龙的干预效果. 广东医学, 2016, 37(10): 1447-1450.
8.	李佳艺, 张程, 李本雪, 等. 甲泼尼龙琥珀酸钠对自身免疫性肺气肿模型大鼠氧化应激和抗内皮细胞抗体的影响. 中国药房, 2020, 31(10): 1208-1212.
9.	刘磊. 系统性红斑狼疮患者血清蛋白 S 与生长阻抑特异性蛋白 6 水平变化及与疾病活动度的相关性研究. 临床和实验医学杂志, 2015, 14(24): 2052-2054.
10.	王艳, 陈燕, 季黎明, 等. 不同血清 25-羟维生素 D 水平的 2 型糖尿病患者颈动脉内膜中层厚度的变化. 临床和实验医学杂志, 2016, 15(5): 445-447.
11.	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013 年修订版). 中华结核和呼吸杂志, 2013, 36(4): 255-264.
12.	Legendre P, Régent A, Thiebault M, et al. Anti-endothelial cell antibodies in vasculitis: a systematic review. Autoimmun Rev, 2017, 16(2): 146-153.
13.	Karayama M, Inui N, Suda T, et al. Antiendothelial cell antibodies in patients with COPD. Chest, 2010, 138: 1303-1308.
14.	包海鹏, 史琦, 阎玥, 等. 分子生物学标志物在 COPD 发病机制中的作用研究概况. 辽宁中医杂志, 2019, 46(6): 1334-1338.
15.	Taraseviciene SL, Douglas IS, Nana-Sinkam PS, et al. Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease?. Proc Am Thorac Soc, 2006, 3(8): 687-690.
16.	Neder JA, de-Torres JP, Milne KM, et al. Lung function testing in chronic obstructive pulmonary disease. Clin Chest Med, 2020, 41(3): 347-366.
17.	Breen M, Nwanaji-Enwerem JC, Karrasch S, et al. Accelerated epigenetic aging as a risk factor for chronic obstructive pulmonary disease and decreased lung function in two prospective cohort studies. Aging (Albany NY), 2020, 12(16): 16539-16554.
18.	赵飘飘. 慢性阻塞性肺疾病综合评估研究及临床意义[D]. 中国医科大学, 2013.
19.	张咪. 慢性阻塞性肺疾病频繁急性加重表型的临床与肺功能研究[D]. 吉林大学, 2020.
20.	殷晓娜, 杨万春. CAT 和 mMRC 评分系统在慢性阻塞性肺疾病病情评估中的应用价值分析. 中国现代医药杂志, 2021, 23(3): 19-22.

1. Vogelmeier CF, Criner GJ, Martínez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Arch Bronconeumol, 2017, 53(3): 128-149.
2. Cheng G, Zhang N, Wang Y, et al. Antibodies of IgG, IgA and IgM against human bronchial epithelial cell in patients with chronic obstructive pulmonary disease. Clin Lab, 2016, 62(6): 1101-1108.
3. Scambler T, Holbrook J, Savic S, et al. Autoinflammatory disease in the lung. Immunology, 2018, 154(4): 563-573.
4. Wen L, Krauss ES, Petersen F, et al. Autoantibodies in chronic obstructive pulmonary disease. Front Immunol, 2018, 25(9): 66.
5. 韦薇, 沈雅萍, 杨翌翔, 等. 血清中抗内皮细胞抗体检测对狼疮性肾炎患者的价值. 国际检验医学杂志, 2017, 38(6): 822-824.
6. Moroncini G, Svegliati BS, Gabrielli A. Agonistic antibodies in systemic sclerosis. Immunol Lett, 2018, 195: 83-87.
7. 马丽, 张璐, 张程, 等. 抗血管内皮细胞抗体在吸烟肺气肿大鼠肺泡隔细胞凋亡中的作用及甲泼尼龙的干预效果. 广东医学, 2016, 37(10): 1447-1450.
8. 李佳艺, 张程, 李本雪, 等. 甲泼尼龙琥珀酸钠对自身免疫性肺气肿模型大鼠氧化应激和抗内皮细胞抗体的影响. 中国药房, 2020, 31(10): 1208-1212.
9. 刘磊. 系统性红斑狼疮患者血清蛋白 S 与生长阻抑特异性蛋白 6 水平变化及与疾病活动度的相关性研究. 临床和实验医学杂志, 2015, 14(24): 2052-2054.
10. 王艳, 陈燕, 季黎明, 等. 不同血清 25-羟维生素 D 水平的 2 型糖尿病患者颈动脉内膜中层厚度的变化. 临床和实验医学杂志, 2016, 15(5): 445-447.
11. 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013 年修订版). 中华结核和呼吸杂志, 2013, 36(4): 255-264.
12. Legendre P, Régent A, Thiebault M, et al. Anti-endothelial cell antibodies in vasculitis: a systematic review. Autoimmun Rev, 2017, 16(2): 146-153.
13. Karayama M, Inui N, Suda T, et al. Antiendothelial cell antibodies in patients with COPD. Chest, 2010, 138: 1303-1308.
14. 包海鹏, 史琦, 阎玥, 等. 分子生物学标志物在 COPD 发病机制中的作用研究概况. 辽宁中医杂志, 2019, 46(6): 1334-1338.
15. Taraseviciene SL, Douglas IS, Nana-Sinkam PS, et al. Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease?. Proc Am Thorac Soc, 2006, 3(8): 687-690.
16. Neder JA, de-Torres JP, Milne KM, et al. Lung function testing in chronic obstructive pulmonary disease. Clin Chest Med, 2020, 41(3): 347-366.
17. Breen M, Nwanaji-Enwerem JC, Karrasch S, et al. Accelerated epigenetic aging as a risk factor for chronic obstructive pulmonary disease and decreased lung function in two prospective cohort studies. Aging (Albany NY), 2020, 12(16): 16539-16554.
18. 赵飘飘. 慢性阻塞性肺疾病综合评估研究及临床意义[D]. 中国医科大学, 2013.
19. 张咪. 慢性阻塞性肺疾病频繁急性加重表型的临床与肺功能研究[D]. 吉林大学, 2020.
20. 殷晓娜, 杨万春. CAT 和 mMRC 评分系统在慢性阻塞性肺疾病病情评估中的应用价值分析. 中国现代医药杂志, 2021, 23(3): 19-22.

Chinese Journal of Respiratory and Critical Care Medicine

Significance of continuous surveillance of anti-endothelial cell antibody in patients with chronic obstructive pulmonary disease

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content